Keyphrases
Predictive Value
100%
Prognostic Value
100%
Stage III Non-small Cell Lung Cancer
100%
Adjuvant Immunotherapy
100%
Durvalumab
100%
Neutrophil-to-lymphocyte Ratio
100%
Confidence Interval
30%
Non-small Cell Lung Cancer Patients
23%
Overall Survival
15%
Progression-free Survival
15%
Definitive Chemoradiation
15%
Immunotherapy Benefits
15%
Treatment Efficacy
7%
Cancer Patients
7%
In Cancer
7%
Predictive Biomarker
7%
Lymphocytes
7%
Eosinophils
7%
Group by
7%
Immune Dysfunction
7%
Veterans Affairs
7%
Basophils
7%
Statistical Interaction
7%
Ratio Level
7%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Durvalumab
100%
Neutrophil
100%
Immunotherapy
100%
Lymphocyte
100%
Overall Survival
15%
Progression Free Survival
15%
Chemoradiotherapy
15%
Biological Marker
7%
Combination Therapy
7%
Malignant Neoplasm
7%
Immune Disorder
7%
Eosinophil
7%
Veterans Affairs
7%
Basophil
7%
Immunology and Microbiology
Durvalumab
100%
Immunotherapy
100%
Neutrophil
100%
Lymphocyte
100%
Overall Survival
15%
Progression Free Survival
15%
Basophil Granulocyte
7%
Eosinophil Granulocyte
7%
Immune System Disorders
7%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Durvalumab
100%
Immunotherapy
100%
Chemoradiation Therapy
15%
Overall Survival
15%
Progression Free Survival
15%
Malignant Neoplasm
7%
Biological Marker
7%
Combination Therapy
7%